New From PubMed:

Researchers at the Skin Institute and School of Dermatology in New Delhi, India, have evaluated the use of tacrolimus in the management of atopic dermatitis for pediatric and adult patients. The immunosuppressive action of tacrolimus has proven effective in the treatment of several inflammatory dermatoses, and has been approved for use in the United States, Europe, Japan, and the Indian subcontinent. Other conditions such as psoriasis, alopecia areata, contact hypersensitivity, vitiligo, and skin grafting/transplant, have been treated successfully with tacrolimus, however, the therapy has not been approved for these indications. Beyond approved uses for atopic dermatitis, tacrolimus efficacy has been measured only in case studies and not by a large-scale controlled study. Given the immunosuppressive nature of tacrolimus, its use should be restricted to instances in which conventional treatment has failed.

Sehgal VN, Srivastava G, and Dogra S. Tacrolimus in dermatology-pharmacokinetics, mechanism of action, drug interactions, dosages, and side effects: part I. Skinmed. 2008 Jan-Feb;7(1):27-30.

Read the full abstract